Oxygen dependence of the metabolic activation and cytotoxicity of tirapazamine: Implications for extravascular transport and activity in tumors

Radiation Research

Volumn 161, Issue 6, 2004, Pages 656-666

  Hicks, Kevin O ^a   Siim, Bronwyn G ^a   Pruijn, Frederik B ^a   Wilson, William R ^a  

^a UNIVERSITY OF AUCKLAND   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

3 AMINO 1,2,4 BENZOTRIAZINE 1 OXIDE; TIRAPAZAMINE; ANTINEOPLASTIC AGENT; OXYGEN; RADIOSENSITIZING AGENT; TRIAZINE DERIVATIVE;

ARTICLE; CANCER INHIBITION; CANCER RADIOTHERAPY; CANCER RESISTANCE; CELL HYPOXIA; CELL STRAIN HT29; CONCENTRATION RESPONSE; DRUG CYTOTOXICITY; HUMAN; HUMAN CELL; METABOLIC ACTIVATION; OXIDATIVE STRESS; PRIORITY JOURNAL; RADIOSENSITIVITY; RADIOSENSITIZATION; BIOLOGICAL MODEL; CARCINOMA; CELL SURVIVAL; COLON TUMOR; COMPARATIVE STUDY; COMPUTER SIMULATION; DOSE RESPONSE; DRUG EFFECT; EVALUATION; METABOLISM; RADIATION DOSE; RADIATION EXPOSURE; TUMOR CELL LINE; VALIDATION STUDY;

ANTINEOPLASTIC AGENTS; CARCINOMA; CELL LINE, TUMOR; CELL SURVIVAL; COLONIC NEOPLASMS; COMPUTER SIMULATION; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; MODELS, BIOLOGICAL; OXYGEN; RADIATION TOLERANCE; RADIATION-SENSITIZING AGENTS; TRIAZINES;

EID: 3042537843     PISSN: 00337587     EISSN: None     Source Type: Journal    
DOI: 10.1667/RR3178     Document Type: Article

References (55)

1. A. W. Fyles, M. Milosevic, R. Wong, M. C. Kavanagh, M. Pintilie, A. Sun, W. Chapman, W. Levin, L. Manchul and R. P. Hill, Oxygenation predicts radiation response and survival in patients with cervix cancer. Radiother. Oncol. 48, 149-156 (1998).
2. 2-measurements as predictive assay in the treatment of carcinoma of the uterine cervix. Radiother. Oncol. 53, 99-104 (1999).
3. D. M. Brizel, R. K. Dodge, R. W. Clough and M. W. Dewhirst, Oxygenation of head and neck cancer: Changes during radiotherapy and impact on treatment outcome. Radiother. Oncol. 53, 113-117 (1999).
4. E. J. Hall and L. Roizin-Towle, Hypoxic sensitizers: Radiobiological studies at the cellular level. Radiology 117, 453-457 (1975).
5. J. K. Mohindra and A. M. Rauth, Increased cell killing by metronidazole and nitrofurazone of hypoxic compared to aerobic mammalian cells. Cancer Res. 36, 930-936 (1976).
6. R. Sridhar, C. Koch and R. Sutherland, Cytotoxicity of two nitroimidazole radiosensitizers in an in vitro tumor model. Int. J. Radiat. Oncol. Biol. Phys. 1, 1149-1157 (1976).
7. G. E. Adams, E. D. Clarke, R. S. Jacobs, I. J. Stratford, R. G. Wallace, P. Wardman and M. E. Watts, Mammalian cell toxicity of nitro compounds: Dependence upon reduction potential. Biochem. Biophys. Res. Commun. 72, 824-829 (1976).
8. J. von Pawel, R. von Roemeling, U. Gatzemeier, M. Boyer, L. O. Elisson, P. Clark, D. Talbot, A. Rey, T. W. Butler and J. Treat, Tirapazamine plus cisplatin versus cisplatin in advanced non-small-cell lung cancer: A report of the international CATAPULT I study group. Cisplatin and tirapazamine in subjects with advanced previously untreated non-small-cell lung tumors. J. Clin. Oncol. 18, 1351-1359 (2000).
9. W. A. Denny and W. R. Wilson, Tirapazamine: A bioreductive anticancer drug that exploits tumour hypoxia. Expert Opin. Investig. Drugs 9, 2889-2901 (2000).
10. D. Rischin, L. Peters, J. Smith, A. Macann, J. Denham, M. Poulsen, M. Jackson, L. Kenny, M. Penniment and R. Fisher, Preliminary results of TROG 98.02-A randomized phase II study of 5-fluorouracil, cisplatin and radiation versus tirapazamine, cisplatin and radiation for advanced squamous cell carcinoma of the head and neck. Proc. Am. Soc. Clin. Oncol. 22 (Suppl.), 495-4 (2003). [abstract]
11. J. Wang, K. A. Biedermann and J. M. Brown, Repair of DNA and chromosome breaks in cells exposed to SR 4233 under hypoxia or to ionizing radiation. Cancer Res. 52, 4473-4477 (1992).
12. J. M. Brown, SR 4233 (tirapazamine): A new anticancer drug exploiting hypoxia in solid tumours. Br. J. Cancer 67, 1163-1170 (1993).
13. Y. M. Delahoussaye, J. W. Evans and J. M. Brown, Metabolism of tirapazamine by multiple reductases in the nucleus. Biochem. Pharmacol. 62, 1201-1209 (2001).
14. R. S. Marshall and A. M. Rauth, Oxygen and exposure kinetics as factors influencing the cytotoxicity of porfiromycin, a mitomycin C analogue, in Chinese hamster ovary cells. Cancer Res. 48, 5655-5659 (1988).
15. A. M. Rauth and R. S. Marshall, Mechanisms of activation of Mitomycin C and AZQ in aerobic and hypoxic mammalian cells. In Selective Activation of Drugs by Redox Processes (G. E. Adams, Ed.), pp. 113-123. Plenum Press, New York, 1990.
16. Y. C. Taylor and A. M. Rauth, Oxygen tension, cellular respiration and redox state as variables influencing the cytotoxicity of the radiosensitizer misonidazole. Radiat. Res. 91, 104-123 (1982).
17. R. T. Mulcahy, Effect of oxygen on misonidazole chemosensitization and cytotoxicity in vitro. Cancer Res. 44, 4409-4413 (1984).
18. B. G. Siim, G. J. Atwell and W. R. Wilson, Oxygen dependence of the cytotoxicity and metabolic activation of 4-alkylamino-5-nitroquinoline bioreductive drugs. Br. J. Cancer 70, 596-603 (1994).
19. W. R. Wilson, J. W. Moselen, S. Cliffe, W. A. Denny and D. C. Ware, Exploiting tumor hypoxia through bioreductive release of diffusible cytotoxins: The cobalt(III)-nitrogen mustard complex SN 24771. Int. J. Radiat. Oncol. Biol. Phys. 29, 323-327 (1994).
20. C. J. Koch, Unusual oxygen concentration dependence of toxicity of SR-4233, a hypoxic cell toxin. Cancer Res. 53, 3992-3997 (1993).
21. B. G. Wouters and J. M. Brown, Cells at intermediate oxygen levels can be more important than the "hypoxic fraction" in determining tumor response to fractionated radiotherapy. Radiat. Res. 147, 541-550 (1997).
22. J. S. Daniels and K. S. Gates, DNA cleavage by the antitumor agent 3-amino-1,2,4-benzotriazine 1,4-dioxide (SR4233): Evidence for involvement of hydroxyl radical. J. Am. Chem. Soc. 118, 3380-3385 (1996).
23. D. Zagorevskii, M. Song, C. Breneman, Y. Yuan, T. Fuchs, K. S. Gates and C. M. Greenlief, A mass spectrometry study of tirapazamine and its metabolites: Insights into the mechanism of metabolic transformations and the characterization of reaction intermediates. J. Am. Soc. Mass Spectrom. 14, 881-892 (2003).
24. R. F. Anderson, S. S. Shinde, M. P. Hay, S. A. Gamage and W. A. Denny, Activation of 3-Amino-1,2,4-benzotriazine 1,4-dioxide antitumor agents to oxidizing species following their one-electron reduction. J. Am. Chem. Soc. 125, 748-756 (2003).
25. G. D. Jones and M. Weinfeld, Dual action of tirapazamine in the induction of DNA strand breaks. Cancer Res. 56, 1584-1590 (1996).
26. J. S. Daniels, K. S. Gates, C. Tronche and M. M. Greenberg, Direct evidence for bimodal DNA damage induced by tirapazamine. Chem. Res. Toxicol. 11, 1254-1257 (1998).
27. J. T. Hwang, M. M. Greenberg, T. Fuchs and K. S. Gates, Reaction of the hypoxia-selective antitumor agent tirapazamine with a Cl′-radical in single-stranded and double-stranded DNA: The drug and its metabolites can serve as surrogates for molecular oxygen in radical-mediated DNA damage reactions. Biochemistry 38, 14248-14255 (1999).
28. R. E. Durand and P. L. Olive, Evaluation of bioreductive drugs in multicell spheroids. Int. J. Radiat. Oncol. Biol. Phys. 22, 689-692 (1992).
29. K. O. Hicks, Y. Fleming, B. G. Siim, C. J. Koch and W. R. Wilson, Extravascular diffusion of tirapazamine: Effect of metabolic consumption assessed using the multicellular layer model. Int. J. Radiat. Oncol. Biol. Phys. 42, 641-649 (1998).
30. A. H. Kyle and A. I. Minchinton, Measurement of delivery and metabolism of tirapazamine to tumour tissue using the multilayered cell culture model. Cancer Chemother. Pharmacol. 43, 213-220 (1999).
31. K. O. Hicks, F. B. Pruijn, J. R. Sturman, W. A. Denny and W. R. Wilson, Multicellular resistance to tirapazamine is due to restricted extravascular transport: A pharmacokinetic/pharmacodynamic study in HT29 multicellular layers. Cancer Res. 63, 5970-5977 (2003).
32. A. I. Minchinton, D. A. Tonn, D. P. Sutherland and A. H. Kyle, Carbogen breathing after irradiation enhances the effectiveness of tirapazamine in SiHa tumors but not SCCVII tumors in mice. Radiat. Res. 158, 94-100 (2002).
33. R. E. Durand and P. L. Olive, Physiologic and cytotoxic effects of tirapazamine in tumor-bearing mice. Radiat. Oncol. Investig. 5, 213-219 (1997).
34. M. P. Hay, S. A. Gamage, M. S. Kovacs, F. B. Pruijn, R. F. Anderson, A. V. Patterson, W. R. Wilson, J. M. Brown and W. A. Denny, Structure-activity relationships of 1,2,4-benzotriazine 1,4-dioxides as hypoxia-selective analogues of tirapazamine. J. Med. Chem. 46, 169-182 (2003).
35. D. W. Whillans and A. M. Rauth, An experimental and analytical study of oxygen depletion in stirred cell suspensions. Radiat. Res. 84, 97-114 (1980).
36. I. F. Tannock, Oxygen diffusion and the distribution of cellular radiosensitivity in tumours. Br. J. Radiol. 45, 515-524 (1972).
37. R. H. Thomlinson and L. H. Gray, The histological structure of some human lung cancers and possible implications for radiotherapy. Br. J. Cancer 9, 539-549 (1955).
38. M. A. Graham, S. Senan, H. Robin, Jr., N. Eckhardt, D. Lendrem, J. Hincks, D. Greenslade, R. Rampling, S. B. Kaye and P. Workman, Pharmacokinetics of the hypoxic cell cytotoxic agent tirapazamine and its major bioreductive metabolites in mice and humans: Retrospective analysis of a pharmacokinetically guided dose-escalation strategy in a phase I trial. Cancer Chemother. Pharmacol. 40, 1-10 (1997).
39. M. A. Baker, E. M. Zeman, V. K. Hirst and J. M. Brown, Metabolism of SR 4233 by Chinese hamster ovary cells: Basis of selective hypoxic cytotoxicity. Cancer Res. 48, 5947-5952 (1988).
40. B. G. Siim, P. L. van Zijl and J. M. Brown, Tirapazamine-induced DNA damage measured using the comet assay correlates with cytotoxicity towards hypoxic tumour cells in vitro. Br. J. Cancer 73, 952-960 (1996).
41. J. M. Vanderkooi, M. Erecinska and I. A. Silver, Oxygen in mammalian tissue: Methods of measurement and affinities of various reactions. Am. J. Physiol. 260, C1131-C1150 (1991).
42. M. I. Walton, M. C. Bibby, J. A. Double, J. A. Plumb and P. Workman, DT-diaphorase activity correlates with sensitivity to the indoloquinone EO9 in mouse and human colon carcinomas. Eur. J. Cancer 28, 1597-1600 (1992).
43. S. Khan and P. J. O'Brien, Molecular mechanisms of tirapazamine (SR 4233, Win 59075)-induced hepatocyte toxicity under low oxygen concentrations. Br. J. Cancer 71, 780-785 (1995).
44. M. I. Walton and P. Workman, Enzymology of the reductive bioactivation of SR 4233. A novel benzotriazine di-N-oxide hypoxic cell cytotoxin. Biochem. Pharmacol. 39, 1735-1742 (1990).
45. R. J. Riley and P. Workman, Enzymology of the reduction of the potent benzotriazine-di-N-oxide hypoxic cell cytotoxin SR 4233 (WIN 59075) by NAD(P)H: (quinone acceptor) oxidoreductase (EC 1.6.99.2) purified from Walker 256 rat tumour cells. Biochem. Pharmacol. 43, 167-174 (1992).
46. J. Wang, K. A. Biedermann, C. R. Wolf and J. M. Brown, Metabolism of the bioreductive cytotoxin SR 4233 by tumour cells: Enzymatic studies. Br. J. Cancer 67, 321-325 (1993).
47. W. R. Wilson, B. G. Siim, J. W. Moselen and S. M. Pullen, Quantitative oxygen dependence (K values) for bioreductive drug cytotoxicity. Proc. Am. Assoc. Cancer Res. 35, 634 (1994).
48. B. G. Wouters, Y. M. Delahoussaye, J. W. Evans, G. W. Birrell, M. J. Dorie, J. Wang, D. MacDermed, R. K. Chiu and J. M. Brown, Mitochondrial dysfunction after aerobic exposure to the hypoxic cytotoxin tirapazamine. Cancer Res. 61, 145-152 (2001).
49. J. H. Elwell, B. G. Siim, J. W. Evans and J. M. Brown, Adaptation of human tumor cells to tirapazamine under aerobic conditions: Implications of increased antioxidant enzyme activity to mechanism of aerobic cytotoxicity. Biochem. Pharmacol. 54, 249-257 (1997).
50. A. I. Minchinton and J. M. Brown, Enhancement of the cytotoxicity of SR 4233 to normal and malignant tissues by hypoxic breathing. Br. J. Cancer 66, 1053-1058 (1992).
51. A. E. Lee and W. R. Wilson, Hypoxia-dependent retinal toxicity of bioreductive anticancer prodrugs in mice. Toxicol. Appl. Pharmacol. 163, 50-59 (2000).
52. B. C. Baguley, K. O. Hicks and W. R. Wilson, Tumour cell cultures in drug development. In Anticancer Drug Development (B. C. Baguley and D. J. Kerr, Eds.), pp. 269-284. Academic Press, San Diego, 2002.
53. Y. M. Delahoussaye, M. P. Hay, F. B. Pruijn, W. A. Denny and J. M. Brown, Improved potency of the hypoxic cytotoxin tirapazamine by DNA-targeting. Biochem. Pharmacol. 65, 1807-1815 (2003).
54. m for radiosensitization of human tumor cells by oxygen is much greater than 3 mmHg and is further increased by elevated levels of cysteine. Radiat. Res. 156, 388-398 (2001).
55. T. W. Secomb, R. Hsu, R. D. Braun, J. R. Ross, J. F. Gross and M. W. Dewhirst, Theoretical simulation of oxygen transport to tumors by three-dimensional networks of microvessels. Adv. Exp. Med. Biol. 454, 629-634 (1998).